Crestor Related Published Studies
Well-designed clinical trials related to Crestor (Rosuvastatin)
Efficacy of early intensive rosuvastatin therapy in patients with ST-segment
elevation myocardial infarction undergoing primary percutaneous coronary
intervention (ROSEMARY Study). [2014]
Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk:
an analysis from the JUPITER Trial (Justification for the Use of Statins in
Prevention: an Intervention Trial Evaluating Rosuvastatin). [2014]
Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo-
and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab
in subjects with hypercholesterolemia on background statin therapy. [2014]
The effect of rosuvastatin on inflammation, matrix turnover and left ventricular
remodeling in dilated cardiomyopathy: a randomized, controlled trial. [2014]
A randomized, double-blind study of fenofibric acid plus rosuvastatin compared
with rosuvastatin alone in stage 3 chronic kidney disease. [2013]
Effect of rosuvastatin on ROCK activity, endothelial function, and inflammation
in Asian patients with atherosclerosis. [2012]
The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial. [2012]
Drug safety evaluation of rosuvastatin. [2011.11]
Rationale and design of STOP DVT study: rosuvastatin for the prevention of deep vein thrombosis in patients undergoing total knee replacement arthroplasty--a prospective randomized open-label controlled trial. [2011.09]
Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial. [2011.08.26]
Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). [2011.08.15]
Effects of rosuvastatin on progression of stenosis in adult patients with congenital aortic stenosis (PROCAS Trial). [2011.07.15]
Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. [2011.07]
Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. [2011.07]
Rosuvastatin in diabetic hemodialysis patients. [2011.07]
Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). [2011.06]
Effect of rosuvastatin on C-reactive protein and progression of aortic stenosis. [2011.06]
The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients. [2011.06]
Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN). [2011.06]
Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-gamma activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A. [2011.06]
Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. [2011.06]
High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. [2011.06]
Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial. [2011.06]
Effects of pravastatin and rosuvastatin on the generation of adiponectin in the visceral adipose tissue in patients with coronary artery disease. [2011.06]
Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. [2011.05.25]
No effect of rosuvastatin in the zoledronate-induced acute-phase response. [2011.05]
Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). [2011.04.19]
Evaluating the effectiveness of rosuvastatin in preventing the progression of diastolic dysfunction in aortic stenosis: A substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study. [2011.02.07]
Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. [2011.02.01]
A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes. [2011.02]
Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus. [2011.02]
Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis. [2011.02]
Rosuvastatin induces apoptosis in CD4(+)CD28 (null) T cells in patients with acute coronary syndromes. [2011.02]
Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. [2011.01]
Aleglitazar, a balanced PPARalpha/gamma agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin. [2011.01]
Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. [2011.01]
Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk >/= 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities. [2011.01]
Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus
rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. [2011]
Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study. [2010.12]
Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. [2010.12]
Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. [2010.11.04]
Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). [2010.10.05]
Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies. [2010.10]
Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters. [2010.10]
Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". [2010.09]
C-reactive protein lowering with rosuvastatin in the METEOR study. [2010.08]
Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). [2010.07.15]
Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA). [2010.07]
Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. [2010.06.01]
Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. [2010.06]
ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. [2010.05]
Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes. [2010.05]
Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. [2010.05]
Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. [2010.04.20]
Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study. [2010.04]
Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. [2010.03.16]
Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism. [2010.03.09]
Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. [2010.03.09]
Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study. [2010.03]
Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. [2010.03]
Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study. [2010.03]
Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia. [2010.03]
Effects of rosuvastatin on coronary flow reserve and metabolic mismatch in patients with heart failure (from the CORONA Study). [2010.02.15]
Prevention of peri-procedural myocardial injury using a single high loading dose of rosuvastatin. [2010.02]
Association of Bicuspid aortic valve morphology and aortic root dimensions: a substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study. [2010.02]
Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. [2010.01.19]
Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). [2010.01.05]
An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. [2010.01]
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. [2010]
One-year treatment with rosuvastatin reduces intima-media thickness in 45 hypercholesterolemic subjects with asymptomatic carotid artery disease. [2010]
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and
rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of
achievement of Joint British Societies (JBS-2) cholesterol targets. [2010]
Statins for the primary prevention of cardiovascular events in women with
elevated high-sensitivity C-reactive protein or dyslipidemia: results from the
Justification for the Use of Statins in Prevention: An Intervention Trial
Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary
prevention trials. [2010]
Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis:
results of the aortic stenosis progression observation: measuring effects of
rosuvastatin (ASTRONOMER) trial. [2010]
Does baseline carotid intima-media thickness modify the effect of rosuvastatin
when compared with placebo on carotid intima-media thickness progression? The
METEOR study. [2010]
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. [2009.12]
Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with non-ischaemic chronic heart failure. [2009.12]
Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. [2009.12]
A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial. [2009.12]
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). [2009.11.10]
Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). [2009.11]
Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment. [2009.11]
Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. [2009.10]
A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events - Reduction of Cholesterol to Key European Targets Trial. [2009.09.09]
Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia. [2009.09]
Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial. [2009.07]
Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage. [2009.07]
Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. [2009.07]
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection. [2009.06]
Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. [2009.06]
Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes. [2009.06]
The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin). [2009.05]
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. [2009.05]
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. [2009.04.30]
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. [2009.04.04]
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. [2009.04.02]
Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia. [2009.04]
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. [2009.04]
Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. [2009.04]
Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. [2009.04]
Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. [2009.04]
Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study. [2009.03.17]
|